

Lindsay A Renfro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4457491/publications.pdf>

Version: 2024-02-01

22
papers

1,147
citations

933264

10
h-index

713332

21
g-index

22
all docs

22
docs citations

22
times ranked

2493
citing authors

#	ARTICLE	IF	CITATIONS
1	Bayesian adaptive trial design for a continuous biomarker with possibly nonlinear or nonmonotone prognostic or predictive effects. <i>Biometrics</i> , 2022, 78, 1441-1453.	0.8	1
2	Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer. <i>Cancer Causes and Control</i> , 2019, 30, 757-765.	0.8	4
3	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1177-1188.	13.9	699
4	Definitions and statistical properties of master protocols for personalized medicine in oncology. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 217-228.	0.4	27
5	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITC (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. <i>European Journal of Cancer</i> , 2018, 103, 205-213.	1.3	13
6	Point estimation following two-stage adaptive threshold enrichment clinical trials. <i>Statistics in Medicine</i> , 2018, 37, 3179-3196.	0.8	7
7	Precision oncology: A new era of cancer clinical trials. <i>Cancer Letters</i> , 2017, 387, 121-126.	3.2	53
8	Prospective Evaluation of a 12-Gene Assay on Patient Treatment Decisions and Physician Confidence in Mismatch Repair Proficient Stage IIA Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 23-30.	1.0	8
9	Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the Power of Pooled Individual Patient Data from Multiple Clinical Trials. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 251-259.	1.0	0
10	Clinical trial designs incorporating predictive biomarkers. <i>Cancer Treatment Reviews</i> , 2016, 43, 74-82.	3.4	61
11	Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials. <i>Chinese Clinical Oncology</i> , 2016, 5, 80-80.	0.4	6
12	Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points. <i>Journal of Biopharmaceutical Statistics</i> , 2015, 25, 857-877.	0.4	9
13	MRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803 Trial. <i>PLoS ONE</i> , 2014, 9, e108483.	1.1	17
14	ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	62
15	Center-within-trial versus trial-level evaluation of surrogate endpoints. <i>Computational Statistics and Data Analysis</i> , 2014, 78, 1-20.	0.7	10
16	CpG Island Methylator Phenotype Is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage III Colon Cancer. <i>Gastroenterology</i> , 2014, 147, 637-645.	0.6	118
17	Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. <i>Projecting Analysis Dates for the IDEA Collaboration. Forum of Clinical Oncology</i> , 2014, 5, 1-7.	0.1	2
18	Germline Variation in Colorectal Risk Loci Does Not Influence Treatment Effect or Survival in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e94727.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. Chinese Clinical Oncology, 2014, 3, .	0.4	5
20	Mining the ACCENT database: a review and update. Chinese Clinical Oncology, 2013, 2, 18.	0.4	7
21	Bayesian Adaptive Trial Design for a Newly Validated Surrogate Endpoint. Biometrics, 2012, 68, 258-267.	0.8	8
22	Bayesian adjusted R^2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials. Statistics in Medicine, 2012, 31, 743-761.	0.8	26